Intravenous immunoglobulin in neurological disease: a specialist review Intravenous immunoglobulin in neurological disease: a specialist review2018-01-17T17:00:38-05:00
Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine2018-01-17T17:00:38-05:00
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS Treatment with laquinimod reduces development of active MRI lesions in relapsing MS2018-01-17T17:00:38-05:00
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R -targeted therapy (daclizumab) in multiple sclerosis Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R -targeted therapy (daclizumab) in multiple sclerosis2018-01-17T17:00:33-05:00
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon B Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon B2018-01-17T17:00:33-05:00
Conflicts of interest in medical science: peer usage, peer review and ‘CoI consultancy’ Conflicts of interest in medical science: peer usage, peer review and ‘CoI consultancy’2018-01-17T17:00:33-05:00
Toward the Development of Rational Therapies in Multiple Sclerosis: What Is on the Horizon? Toward the Development of Rational Therapies in Multiple Sclerosis: What Is on the Horizon?2018-01-17T17:00:25-05:00
FTY720, a novel once-daily oral medication, shows promising results in treatment of multiple sclerosis FTY720, a novel once-daily oral medication, shows promising results in treatment of multiple sclerosis2018-01-17T17:00:25-05:00
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis2018-01-17T17:00:21-05:00
The protease inhibitor, Bowman Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis The protease inhibitor, Bowman Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis2018-01-17T17:00:21-05:00
